Why the study?
The introduction of DOACs has lowered the threshold for anticoagulation and increased use in elderly patients with AF, alongside growing occurrences of unexpected surgeries during anticoagulant therapy.
Absolute Event Rate: 1.2% vs 1.8%
p-value: p=0.410
This review discusses the indications, practical use, and perioperative management of oral anticoagulants (DOACs) in patients with atrial fibrillation, including the elderly.
心房細動（atrial fibrillation：AF）患者の心原性脳塞栓症予防は変革の時を迎えている．Direct oral anticoagulant（DOAC）の登場により，抗凝固療法開始の敷居は低くなり，また，その安全性から，高齢AF患者への使用も増加している．それに伴い，抗凝固薬投与中の患者が予期せぬ手術を受ける機会も増えている．そこで，本稿では，AF患者における抗凝固療法の適応と実際の使用法，周術期管理から高齢者の抗凝固薬投与の適応等，自施設データやエビデンスを踏まえ，解説することとする．
No takes yet. Share an insight, caveat, or question.
Okumura et al. (2019) conducted a review in Atrial fibrillation (n=3,237). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Stroke, transient ischemic attack (TIA), or systemic embolism (p=0.410).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: